Literature DB >> 25685533

CD4(+) CD25(+) cells in type 1 diabetic patients with other autoimmune manifestations.

Dalia S Abd Elaziz1, Mona H Hafez1, Nermeen M Galal1, Safa S Meshaal2, Aisha M El Marsafy1.   

Abstract

The existence of multiple autoimmune disorders in diabetics may indicate underlying primary defects of immune regulation. The study aims at estimation of defects of CD4(+) CD25(+high) cells among diabetic children with multiple autoimmune manifestations, and identification of disease characteristics in those children. Twenty-two cases with type 1 diabetes associated with other autoimmune diseases were recruited from the Diabetic Endocrine and Metabolic Pediatric Unit (DEMPU), Cairo University along with twenty-one normal subjects matched for age and sex as a control group. Their anthropometric measurements, diabetic profiles and glycemic control were recorded. Laboratory investigations included complete blood picture, glycosylated hemoglobin, antithyroid antibodies, celiac antibody panel and inflammatory bowel disease markers when indicated. Flow cytometric analysis of T-cell subpopulation was performed using anti-CD3, anti-CD4, anti-CD8, anti-CD25 monoclonal antibodies. Three cases revealed a proportion of CD4(+) CD25(+high) below 0.1% and one case had zero counts. However, this observation did not mount to a significant statistical difference between the case and control groups neither in percentage nor absolute numbers. Significant statistical differences were observed between the case and the control groups regarding their height, weight centiles, as well as hemoglobin percentage, white cell counts and the absolute lymphocytic counts. We concluded that, derangements of CD4(+) CD25(+high) cells may exist among diabetic children with multiple autoimmune manifestations indicating defects of immune controllers.

Entities:  

Keywords:  Autoimmunity; CD4+ CD25+ cells; Children; T regulatory cells; Type1 diabetes mellitus

Year:  2013        PMID: 25685533      PMCID: PMC4293905          DOI: 10.1016/j.jare.2013.09.004

Source DB:  PubMed          Journal:  J Adv Res        ISSN: 2090-1224            Impact factor:   10.479


Introduction

Diabetes mellitus (DM) is a common chronic, metabolic syndrome; which results in hyperglycemia as a cardinal biochemical feature. Type 1 diabetes is the most common type of diabetes in children and adolescents. Type 1 diabetes is caused by deficiency of insulin secretion due to pancreatic B-cell damage. Most cases of type 1 diabetes are primarily due to T-cell mediated pancreatic islet β-cell destruction, which occurs at a variable rate. There are usually serological markers of an autoimmune pathologic process, including islet cell antibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD), the insulinoma-associated 2 molecule (IA-2)and zinc transporter 8 (ZnT-8) [1]. Autoimmune features were considered as associations with immunodeficiency disorders but are now viewed as an important component of some diseases attributed to the breakdown of self –tolerance or defects of immune regulators [2]. Furthermore some Primary Immune Deficiencies (PID) classifications now divide diseases according to the frequency of autoimmune features [3]. CD4+ CD25+ T cells were named regulatory T cells (T reg) and since then have been intensively characterized by many groups. It has now been well documented in a variety of models that CD4+CD25+ play indispensable roles in the maintenance of natural self-tolerance, in averting autoimmune responses, as well as in controlling inflammatory reactions [4,5]. Type 1 diabetes is a common presenting feature in primary immune deficiency disorders affecting immune control like Immunedysregulation Polyendocrinopathy Enteropathy X-linked syndrome (IPEX), Autoimmune Polyendocrinopathy Candidiasis-Ectodermal dystrophy (APECED) and Common Variable Immunedeficiency (CVID) [6,7]. The autoimmune disorders are often present or can even prevail over recurrent infections when the genetic defect affects regulatory T (Treg) cells, which are the major players in maintaining peripheral tolerance [8]. Treg cell subset is impaired in IPEX syndrome; a disease caused by mutations in fork head box p3 (FOXP3) gene, the master switch for the function of Treg cells [9]. Notably, around one third of the patients, with clinical manifestation closely resembling IPEX syndrome, FOXP3 is not mutated, these patients are referred to as IPEX like [10]. The contributions of an altered Treg cell in the pathogenesis of IPEX like syndromes remain elusive [11]. Treg cell detection and quantification in humans have been limited by the fact that the main markers of their identification, CD25+ and FOXP3+ are also expressed by the activated Teff cells, which can be increased in inflammatory conditions, typically in autoimmune diseases [9,12]. The study aims at estimation of the defects of CD4+ CD25+high cells among diabetic children with multiple autoimmune manifestations, diagnosis of underlying primary immunodeficiency disorders and indentification of disease characteristics in those children.

Subjects and methods

The study protocol was approved by the Institutional Review Board and the Ethical Committee of Cairo University, Egypt and informed consents were obtained from the patients’ guardians. Twenty-two children (12 females and 10 males) with type 1 diabetes associated with other autoimmune diseases were enrolled from the Diabetic Endocrine and Metabolic Pediatric Unit (DEMPU) of Cairo University from 2011 to 2012. Inclusion criteria: Type 1 diabetes mellitus with one or more of the following features: autoimmune enteropathy, autoimmune thyroiditis, autoimmune hemolytic anemia, autoimmune hepatitits and/or alopecia. Twenty-one healthy subjects matched for age and sex were assessed as a control group with no signs or symptoms of autoimmune, chronic, inflammatory and neoplastic diseases. Detailed history taking, clinical examination with emphasis on anthropometric parameters and glycemic control over the last year of the patients were taken. Laboratory investigations included: complete blood picture, glycosylated hemoglobin, antithyroid antibodies, Celiac antibody profile and inflammatory bowel disease profile when indicated. Peripheral venous blood was drawn using tubes containing EDTA. Blood samples were processed within 2 h of collection.

Monoclonal antibodies

Phycoerythrin(PE)-conjugated monoclonal anti-CD4(Catalog number FAB3791P), Phycoerythrin(PE)-conjugated monoclonal anti-CD8 (Catalog number FAB1509P), fluorescein isothiocyanate (FITC)-conjugated anti-CD3(Catalog number FAB100F) from R&D Systems Company and phycoerythrin cyanin 5 (PE-cy5)-conjugated anti-CD25(Catalog number 555433) from BD Bioscience Company.

Flow cytometric analysis

Immunofluorescence staining was performed on whole blood. For each case; two test tubes were prepared; in each 50 μl of whole blood was added to the appropriate amount of the monoclonal anti-bodies (5 μl). Simultaneous staining for CD3, CD4, CD25 was done and CD3 together with CD8 in the other tube. Background fluorescence was assessed using the appropriate isotype- and fluorochrome-matched control monoclonal antibody to determine the percentage of positive cells. Lymphocytes were gated on by their forward and side scatter properties, and CD3+CD4+CD25+high cells were determined within the lymphocytes gate. Antibody staining analysis was performed on Beckman Coulter Elite XL flow cytometer FACSE. These reagents were provided by Cairo University, there was no other source of funding during conduction of the study included.

Statistical analysis

Parametric quantitative data were presented by mean and standard deviation (SD) and compared by t-student test. Nonparametric quantitative data were presented by median and interquartile range (IQR) and compared by Mann U Whitney test. Continuous data were correlated by Pearson correlation and presented by scatter plot. Receiver Operator Characteristic (ROC) curve were constructed to assess the association between CD4+ CD25+ in relation to endocrinal complication.

Results

The age of the patients ranged from 4.1 to 20.8 years (median 11.6). There were 10 males and 12 females. Consanguinity was positive in six patients from the case group (27.3%). The average duration of diabetes was equal to five years and seven months. The first presentation at diagnosis of diabetes mellitus (DM) was Diabetic Ketoacidosis (DKA) in 18.2% of the patients and hyperglycemia in 81.8%. Six patients received immunosuppressive drugs and eight patients received thyroxin replacement. Most of our patients suffered acute diabetic complications such as severe hypoglycemia (31.8%) and DKA (54.6%). Regarding the hypoglycemic attacks, one patient had frequent attacks of hypoglycemia before being diagnosed as Addison disease, another patient was newly diagnosed, whereas the other patients had infrequent attacks and were often related to their activity or receiving the dose of insulin without taking the proper diet. Regarding the growth parameters there were significant statistical differences between the case and control groups regarding their height, weight according to the Egyptian growth chart, with P-value of 0.004, 0.05 respectively as shown in Table 1.
Table 1

Comparison between the case and control groups regarding their growth parameters: (Mann Whitney U test).

NumberMedianIQRP-value
Weight SDSCase22−.7003.40.05 (S)
Control21.1002.1



Height SDSCase22−1.2503.20.004 (S)
Control21−.2001.9

IQR: Inter quartile range.

SDS: standard deviation score.

P < 0.05.

Seven patients were short in stature (below the 3rd percentile for age and sex) as shown in Fig. 1. Cases numbers (2, 3) were diagnosed as type 1DM, autoimmune thyroid disease and Celiac disease. Cases numbers (1, 6) were diagnosed as type1 DM and hypothyroid Hashimoto’s thyroiditis. Case number (9) was diagnosed as type1 DM and Wolloct–Rallison Syndrome. Case number (13) was diagnosed as type1 DM and Celiac disease. Case number (22) was diagnosed as type1 DM and autoimmune hemolytic anemia with alopecia. Six patients also had delayed pubertal stages for their age cases no (1, 3, 4, 8, 9 and 13).
Fig. 1

Comparison between cases and control groups regarding their height on the Egyptian growth chart (percentiles).

The study group had poor glycemic control. Five patients had glycosylated hemoglobin levels HbA1c >8.5% (69 mmol/mol), while thirteen cases had HbA1c >8% (64 mmol/mol), with duration of diabetes 5.73 years, SDS (5.08), putting them at risk of the chronic complications of diabetes. Six of these patients (27.3%) had renal complication in the form of persistent microalbuminuria or slight impairment of the renal function, five of them had a duration of diabetes >5 years cases no (1, 2, 8, 9 and 20) and only one patient with 3.2 years duration case no (14). The renal affection of the former patient cannot be contributed to diabetes alone as this patient had multiple autoimmune phenomena and was diagnosed as Systemic Lupus Erythematosus (SLE). Two patients (9.1%) suffered from neuropathy and one patient (4.5%) from arthropathy. The most frequent clinical autoimmune feature associated with type 1 diabetes in the cases was endocrinopathy (77.2%) in the form of Hashimoto’s thyroiditis with positive antithyroid antibodies followed by enteropathy in 27.2% of the cases. The celiac patients represented 22.7% of the total patients whereas inflammatory bowel disease constituted 9% (one patient had Celiac and Ulcerative colitis diseases, case no 8). There was one case with autoimmune hepatitis, one case with autoimmune hemolytic anemia and one case diagnosed as Systemic Lupus Erythematosus (SLE) as demonstrated in Table 2.
Table 2

Clinical pattern and glycemic control in the case group.

NoAgeOnet of DMClinical featuresInfectionsNo of DKATherapyHbA1c% (mmol/ml)CD4+ CD25+high %
113.46.25Hypothyroid HT, STNo2Thyroxin10.8%(95)0.44
27.72.55Celiac, hypothyroid HT, STHepatitis A1Thyroxin15%(140)0.28
314.47.17Celiac, Euthyroid HT, STNo67.4%(57)0.28
412.35.23Euthyroid HTSepsis (ICU) admission29.5%(80)0.45
510.98.63Hypothyroid HTRTI0Thyroxin7.2%(55)0.36
6114.42Hypothyroid HT, STNo1Thyroxin8.4%(68)0.19
75.44.73Hypothyroid HTNo1Thyroxin7.1%(54)0.29
811.11.27Celiac, Ulcerative colitis, Euthyroid HTURTI, Pneumonia, GIT with Entamoeba histolytica0IS8.4%(68)0.07
912.10.2Autoimmune hepatitis, ST, (Wolcott-Rallison Syndrome)Otitis media, Chicken Pox, Roseola infection UTI with Klebsiella1IS10.5%(91)0.09
1011.54.8Hypothyroid HTNo0Thyroxin11.5% (102)0.48
116.435.38Euthyroid HTNo06.9%(52)0.88
1218.82.9CeliacRTI>1012.5% (113)0.45
1314.59.9Celiac, STRTI113%(119)0.38
1412.449.7Euthyroid HT Aplastic anemia, SLEEBV , CMV Oral moniliasis Wound infection with Klebsiella and Pseudomonas0IS5%(31)0.0
1510.099.2Euthyroid HTNoO7.45%(58)0.28
164.13Euthyroid HTNO07.4%(57)0.43
1715.5812.3Crohns disease Epiliptogenic dysfunction by EEGRTI Otitis media0IS10.2%(88)1.41
189.127.9Euthyroid HTNO19.6%(81)0.07
1914.158Hypothyroid HTNO1Thyroxin8.5%(69)1.15
2015.29.5Euthyroid HT, Addison diseaseNo1Asitonin H, Hydrocortisone.12.2% (110)0.28
2120.871Hypothyroid HT, Alopecia, neutropeniaRecurrent oral, vaginal ulcers and superficial abscess0Thyroxin7.7%(61)0.79
225.355.3Hepatitis? Alopecia Autoimmune hemolytic anemia0IS6.3%(57)0.47

Legend; DM: diabetes mellitus, DKA: diabetic ketoacidosis, HbA1c: glycosylated heamoglobin, HT: Hashimoto thyroiditis, RTI: respiratory tract infection, URTI: upper respiratory tract infection, GIT: gastroenteritis, IS: immunosuppressive drugs, EBV: Epstein barr virus, CMV: Cytomegalovirus, EEG: electroencephalogram, ST:short stature, ICU: intensive care unit.

Regarding the blood counts in the case group, there were three patients with leucopenia with white blood cell counts (WBC) ⩽ 4 × 10.e3/μl (cases # 2, 14, 17). There were five patients with neutropenia with absolute neutrophilic counts (ANC) < 1500, case no 1(1290), case no 2(880), case no 14 (575), case no 17(816) and case no 21 (1300). There were two patients with lymphopenia case no 8 with an absolute lymphocytic count (ALC) of (1222) and case no 17 (1344). Significant statistical differences were observed between case and control groups regarding hemoglobin percentage, WBC’s and the absolute lymphocytic counts with P-values of 0.01, 0.01, 0.004, respectively as shown in Table 3.
Table 3

Comparison between case and control groups regarding the Hemoglobin, WBC’s and T cell subpopulations.

Group (n)MeanSDP value
Hemoglobin (g/dl)Case (22)11.4911.45270.01
Control (21)12.400.5128
WBC’s (×10.e3/μl)Case6.4643.02880.010
Control8.5241.7815
Neutrophil (%)Case44.95%12.1240.441
Control47.52%9.250
ANCCase3108.772028.5150.085
Control4039.101338.911
Lymph (%)Case45.59%11.9270.724
Control44.48%8.232
ALCCase2763.551071.280.004
Control3805.521153.876
CD3+%Case63.364%7.61000.348
Control60.810%9.9257
Absolute no of CD3+Case1730.45687.8400.019
Control2300.57840.763
CD3+CD4+ %Case35.01%7.13930.360
Control37.071%7.4078
Absolute no of CD3+CD4+Case934.14336.2220.002
Control1371.1495.052
CD3+CD8+ %Case28.268%6.71490.029
Control23.762%6.3231
Absolute no of CD3+CD8+Case800.55428.0110.415
Control901.81374.601
CD4+CD25+high %Case0.430%0.349130.82
Control0.4086%0.2643
MFICase0.551.3420.069
Contol2.935.834
Absolute no of CD4+CD25+highCase3.04123.730.099
Control4.23805.55

WBC: white blood cells, ANC: absolute neutrophilic count.

ALC: absolute lymphocytic count.

The absolute count of CD4+CD25+ was done by Mann Whitney U test (Median, IQR), the others were done by T-test.

P < 0.05.

As for CD Counts, there were statistically significant differences regarding the absolute CD3+ count, the absolute CD4+ counts and the CD8+ percentage results between the case and control groups, with P-values of 0.019, 0.002 and 0.02 respectively as seen in Table 3 and Fig. 2.
Fig. 2

Comparison of the absolute number of CD3+ CD4+ in cases and control group.

Four cases showedCD4+CD25+high percent less than 0.1%, (cases numbers 8, 9, 14 and 18), and their clinical features as well as infection histories were described in Table 2. The lower percentage of CD4+CD25+high was a continuous not transient event, in case no (9) immunosuppressive treatment was stopped five years ago before the study while in case no (18) immunosuppressive drugs were never received, as for case no (8) she was on Azathioprine and Pentaza during the study and regardingcase no (14) he was on pulse steroid therapy, Sandimmune and Cellcept. The flow cytometry results of patient number 14 show CD4+ CD25+% = 0% in Fig. 3. There was no statistically significant difference between the two studied groups regarding the percentages or the absolute number of CD4+CD25+high by analysis of Roc curve as in Fig. 4 and Fig. 5.
Fig. 3

Flow cytometric results of patient 14: The lymphocyte, as it was identified by their forward and side scatter properties were gated for coexpression of CD4+ and CD25+high. CD4+CD25+high = 0%.

Fig. 4

By analyzing the Roc curve of absolute CD4+ CD25+high it did not achieve under the curve >65% and it was of no significant P-value.

Fig. 5

Whisker and box plot comparison of the absolute counts of CD4+ CD25+high in both cases and control groups.

Also there was no statistically significant difference between mean fluorescence intensity MFI in patients when compared to the healthy group (See Fig. 6).
Fig. 6

Flow cytometric results of patient 9: The lymphocyte, as it was identified by their forward and side scatter properties were gated (a) for co expression of CD4+ and CD25+high. CD4+CD25+high = 0.09% (b) compared to one of the healthy controls (c and d) where the CD4+CD25+high = 1.37%.

Discussion

The consanguinity rate in the diabetic group was (27.3%), higher rates were reported in Saudi diabetic children [13]. In another study investigating cases with CD25+ deficiency, only two male patients were described; one of them from a positive consanguineous family [14]. In our study group, four patients (18.2%) presented by DKA as a first manifestation of T1DM, this frequency is limited to our group only, as it is lower than the frequency of DKA being a first presentation in Diabetic Endocrine and Metabolic Pediatric Unit (DEMPU), which receives 30–50 newly diagnosed type1 diabetic patients monthly, with 30–40% of them presenting with DKA (personal communication) as well as other studies with a range of 26.3–55.3% [15,16]. Formerly, Type1 DM was known to have adverse effects on linear growth and pubertal development [17]. However, with recent insulin treatment regimens and monitoring of blood glucose level, growth has substantially improved and height in children with TIDM today should be similar in all ages to the height of their unaffected peers [18]. The significant statistical differences between the case and the control groups regarding their height and weight point to the multifactorial influence of their disease conditions, associations and treatment regimens. Five patients of them had glycosylated hemoglobin levels (HbA1c) more than 8.5%, while 13 cases had HbA1c of more than 8% indicating poor control. These results are in concordance with Danne et al. who showed a direct correlation between increased glycosylated heamoglobin levels and standing height SDS reduction [19] and Gunczler et al. who also showed that children with poor control have a significantly lower growth velocity compared with well controlled subjects [20]. On the other hand, the development of chronic complications in diabetes is related to the hyperglycemia that persists even with treatment of the disease, it is also dependent on the duration of diabetes [21]. Our results showed that diabetic nephropathy was the most common complication among this cohort of diabetic patients, in concordance with other studies [22]. In contrast other studies reported a different incidence, where retinopathy was the most common complication followed by neuropathy and nephropathy [13]. Two patients (9.1%) had neuropathy, one patient with duration of diabetes of 19.2 years case no (21) and the other patient case no (14) was diagnosed as autoimmune polyneuropathy. Several autoimmune features were detected in some cases necessitating vigilance to pick up those problems that may present in a subtle form in diabetics. Thyroid autoantibodies ranked first as the most commonly associated autoimmune disorder among diabetic patients in concordance with studies that estimate percentage ranging from 11% to 46% of diabetic patients with either thyroid peroxidase antibodies or thyroglobulin antibodies [23]. The prevalence of Celiac disease in patients with diabetes ranges from 4.4% to 11.1% compared to the general population [24,25]. In our study group the celiac patients represented 22.7% of the total patients whereas inflammatory bowel disease constituted 9% of the study group. There was a significant statistical difference between cases and controls groups in hemoglobin percentage and white blood counts with P-values (0.01, 0.01 respectively). These results are similar to those observed in laboratory abnormalities in IPEX and IPEX like syndrome where cytopenia (anemia, leucopenia, and thrombocytopenia) may be present [6,26]. Regarding CD4+ CD25+high proportions, there were four patients with values of less than 0.1% however values did not mount to a statistical difference between the absolute numbers of CD4+ CD25+high cells between the control and cases groups. These results were in concordance with Lindely et al. and Putnam et al., who reported that there was no significant difference in the percentage of CD4+ CD25+high between patients and healthy subjects as well as in the level of CD4+CD25+high expression per cell, when expressed as the mean fluorescence intensity [27,28] and are against Luczynski et al. who found significant statistical difference between newly diagnosed type 1diabetes patients and normal children as regards CD4+CD25+% but not the absolute counts ∗∗[29]. One explanation may be due to CD4+CD25+ expression by the activated T effectors cell which can be increased in inflammatory and autoimmune diseases [12]. Another explanation is that Treg may demonstrate reduced functional capacity with drop of CD4+ CD25+ levels over time [30]. Other studies indicate the defect may involve the number and/or function of Tregs in type 1 DM [31]. Barzaghi et al., reported that CD4+ CD25+ FOXP3+ T cells median values obtained in IPEX-like patients were not significantly lower than those detected in healthy controls, but by using demethylation analysis of FOXP3 locus; results showed quantitative defect of regulatory T cells in patients thanhealthy control with statistical significance difference [11]. In case no 14, the patient was diagnosed as SLE while his CD4+ CD25+% was zero. This patient suffered from polyneuropathy followed by diabetes then two years later he developed pancytopenia, with positive Anti nuclear Antibodies (ANA), Anti double stranded Antibodies (Anti DNA), and development of rapid renal affection with lupus cerebritis. He also had positive anti-thyroglobulin antibodies and anti-microsomal antibodies with normal thyroid function. This finding was similar to most of studies that found a significant decreased percentage of CD4+ CD25+ cells in patients with SLE as compared to healthy controls [32-34]. Other studies showed that patients who were untreated and/or newly diagnosed with SLE, showed negative correlation between percentage of CD4+CD25+ and the clinical activity of the disease, this was also noted with pediatric patients and some studies reported an inverse correlation between number of CD4+CD25+ and disease activity as well as autoantibody levels [33,35].

Limitations

Several study limitations were encountered, the small sample size because of the rarity of the condition. The confounding effect of immunosuppressive therapy which could not be stopped due to severity of the disease, functional Treg assays were not conducted and might have explained why there were patients with CD4+CD25+high similar to controls. Further studies with Foxp3 expression need to be assessed as it is a key for Treg regulation mechanisms, using the demethylation methods.

Conclusions

In conclusion, diabetic children with multiple autoimmune features may demonstrate CD4+CD25+high cells deficiency favoring the immune disequilibrium.

Conflict of interest

The authors have declared no conflict of interest.
  34 in total

1.  The Mauriac syndrome: dwarfism, hepatomegaly and obesity with juvenile diabetes mellitus.

Authors:  G M GUEST
Journal:  Diabetes       Date:  1953 Sep-Oct       Impact factor: 9.461

2.  Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus.

Authors:  Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Yao-Hsu Yang; Dong-Tsamn Lin; Bor-Luen Chiang
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

3.  Prevalence of coeliac disease in children and adolescents with type 1 diabetes mellitus in a clinic based population.

Authors:  C Goh; K Banerjee
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

Review 4.  Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome.

Authors:  R S Wildin; S Smyk-Pearson; A H Filipovich
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

5.  Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus.

Authors:  H-Y Lee; Y-K Hong; H-J Yun; Y-M Kim; J-R Kim; W-H Yoo
Journal:  Rheumatology (Oxford)       Date:  2008-04-03       Impact factor: 7.580

Review 6.  Primary immunodeficiencies unravel critical aspects of the pathophysiology of autoimmunity and of the genetics of autoimmune disease.

Authors:  Antonio Coutinho; Magda Carneiro-Sampaio
Journal:  J Clin Immunol       Date:  2008-02-22       Impact factor: 8.317

Review 7.  Clinical and molecular aspects of autoimmune enteropathy and immune dysregulation, polyendocrinopathy autoimmune enteropathy X-linked syndrome.

Authors:  Frank M Ruemmele; Nicolette Moes; Natacha Patey-Mariaud de Serre; Frédéric Rieux-Laucat; Olivier Goulet
Journal:  Curr Opin Gastroenterol       Date:  2008-11       Impact factor: 3.287

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

10.  Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome.

Authors:  F Barzaghi; L Passerini; E Gambineri; S Ciullini Mannurita; T Cornu; E S Kang; Y H Choe; C Cancrini; S Corrente; R Ciccocioppo; M Cecconi; G Zuin; V Discepolo; C Sartirana; J Schmidtko; A Ikinciogullari; A Ambrosi; M G Roncarolo; S Olek; R Bacchetta
Journal:  J Autoimmun       Date:  2012-01-20       Impact factor: 7.094

View more
  2 in total

1.  Flow cytometry optimizing the diagnostic approach in inborn errors of immunity: experience from Egypt.

Authors:  Safa Meshaal; Rabab Ei Hawary; Alia Eldash; Aya Erfan; Dalia Abd Elaziz; Radwa Alkady; Sohilla Lotfy; Nermeen Galal; Jeannette Boutros; Aisha Elmarsafy
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-02       Impact factor: 3.373

2.  Differential Expression of IL-10 Gene and Protein in Target Tissues of Rattus Norvegicus Strain Wistar Model Type 2 Diabetes Mellitus (T2DM).

Authors:  Yohanes Bare; Agung Pramana Warih Marhendra; Tomohiko Sasase; Fatchiyah Fatchiyah
Journal:  Acta Inform Med       Date:  2018-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.